Abstract
To explore apolipoprotein E gene variants distribution among the patients of Alzheimer’s disease and vascular dementia for the elderly community population in Nanking, the polymerase chain reaction and restriction fragment length polymorphism techniques were employed to analyze the gene frequency of apolipoprotein E (ApoE) for 113 cases with Alzheimer’s disease (AD), 85 cases with vascular dementia (VaD), 147 cases with questionable dementia (QD), and 396 dementia-free controls. It was found that ApoE ε4 gene container (37.17%) and allele frequency (21.24±2.72) of ApoE ε4 in AD group were significantly higher than those in both control and VaD group (p<0.05). With the increment of ε4 gene dose, the incidence of the AD was significantly increased. Compared with the control group, ApoE ε4 had risk ratio (RR) of 1.82 to develop AD (p =4e-4), and attributable risk percentage (ARP) of 45%. These results suggest that ApoE ε4 gene may be responsible for up to 45% of the genetic component of Alzheimer’s disease, and may act as a discriminator between AD and VaD as well.
Keywords: Alzheimer’s disease, vascular dementia, apolipoprotein E.
Medicinal Chemistry
Title:Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking
Volume: 10 Issue: 8
Author(s): Wen-Zheng Chu, Li Gong, Ying-Qiu Xu, Guo-Hua Cai and Kuo-Chen Chou
Affiliation:
Keywords: Alzheimer’s disease, vascular dementia, apolipoprotein E.
Abstract: To explore apolipoprotein E gene variants distribution among the patients of Alzheimer’s disease and vascular dementia for the elderly community population in Nanking, the polymerase chain reaction and restriction fragment length polymorphism techniques were employed to analyze the gene frequency of apolipoprotein E (ApoE) for 113 cases with Alzheimer’s disease (AD), 85 cases with vascular dementia (VaD), 147 cases with questionable dementia (QD), and 396 dementia-free controls. It was found that ApoE ε4 gene container (37.17%) and allele frequency (21.24±2.72) of ApoE ε4 in AD group were significantly higher than those in both control and VaD group (p<0.05). With the increment of ε4 gene dose, the incidence of the AD was significantly increased. Compared with the control group, ApoE ε4 had risk ratio (RR) of 1.82 to develop AD (p =4e-4), and attributable risk percentage (ARP) of 45%. These results suggest that ApoE ε4 gene may be responsible for up to 45% of the genetic component of Alzheimer’s disease, and may act as a discriminator between AD and VaD as well.
Export Options
About this article
Cite this article as:
Chu Wen-Zheng, Gong Li, Xu Ying-Qiu, Cai Guo-Hua and Chou Kuo-Chen, Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking, Medicinal Chemistry 2014; 10 (8) . https://dx.doi.org/10.2174/1573406410666140327120714
DOI https://dx.doi.org/10.2174/1573406410666140327120714 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design Involvement of Advanced Glycation End-products (AGEs) in Alzheimers Disease
Current Alzheimer Research The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Association of Newly Diagnosed Hypertension and Polypharmacy with Frailty in a Tertiary Hospital Patients from Maracaibo City, Venezuela
Current Hypertension Reviews Transdermal Drug Delivery Systems and their Potential in Alzheimer’s Disease Management
CNS & Neurological Disorders - Drug Targets QSAR and Molecular Modeling Studies on a Series of Pyrrolidine Analogs Acting as BACE-1 Inhibitors
Letters in Drug Design & Discovery Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients
Reviews on Recent Clinical Trials Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Current Pharmaceutical Biotechnology Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Statin Treatment and Carotid Plaque Composition: A Review of Clinical Studies
Current Vascular Pharmacology Bipolar Affective Disorder, Epilepsy and Migraine – Does Possible Shared Pathogenesis Explain their Association?
Current Psychopharmacology